Liminatus Pharma Inc. (NASDAQ:LIMN) Sees Significant Drop in Short Interest

Liminatus Pharma Inc. (NASDAQ:LIMN) was the target of a large decrease in short interest in April. As of April 30th, there was short interest totaling 1,083,465 shares, a decrease of 45.5% from the April 15th total of 1,989,468 shares. Based on an average daily volume of 2,651,998 shares, the short-interest ratio is presently 0.4 days. Currently, 2.4% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Liminatus Pharma in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Liminatus Pharma Trading Up 3.9%

LIMN traded up $0.01 during trading on Monday, hitting $0.19. The company’s stock had a trading volume of 1,223,686 shares, compared to its average volume of 7,651,536. Liminatus Pharma has a twelve month low of $0.16 and a twelve month high of $33.66. The business’s fifty day simple moving average is $0.20 and its 200 day simple moving average is $0.60. The firm has a market capitalization of $8.40 million and a price-to-earnings ratio of -0.43.

Liminatus Pharma (NASDAQ:LIMN) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.03) EPS for the quarter.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.